2022 Fiscal Year Final Research Report
Development of a treatment for type 1 diabetes using human iPS-derived pancreatic beta cell sheets
| Project/Area Number |
19K17968
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 54040:Metabolism and endocrinology-related
|
|---|
| Research Institution | Tokyo Women's Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2019-04-01 – 2023-03-31
|
| Keywords | iPS細胞 / 再生医療 / p53 / 増殖能 / 膵島 / 脂肪由来間質細胞 |
|---|
| Outline of Final Research Achievements |
The islet transplantation currently performed in the world requires multiple transplants due to the shortage of donors, and regenerative medicine is expected. β-cell regeneration using iPS cells and ES cells has been studied worldwide, but the functional immaturity of transplanted β-cells in animal experiments has been an issue. In this study, we focused on the establishment of a new transplantation method and the proliferative ability of β cells.
They induced pancreatic progenitor cells from iPS cells (because the induction efficiency of β cell differentiation was low) and succeeded in producing a co-culture sheet (fibrin gel sheet) with adipose-derived stromal cells, which are considered to be necessary for anti-inflammatory reactions and angiogenesis. p53 may be an important factor for the proliferative ability of pancreatic islets during their maturation process.
|
| Free Research Field |
糖尿病代謝内科
|
| Academic Significance and Societal Importance of the Research Achievements |
1型糖尿病や膵臓全摘術後の治療はインスリン投与が必須となっている。根治術として膵島移植は行われているが、ドナー不足により複数回の移植が必要となるなど課題も多い。膵島の再生医療及び移植方法の確立は今後の１型糖尿病の完治治療となる可能性がある。今後更なる研究により臨床に応用されることを願っている。
|
